SI-BONE, Inc. (NASDAQ:SIBN) is reporting second quarter financial results on Monday 3rd August 2020, after market close.
According to analysts surveyed by Thomson Reuters, SIBN is expected to report 2Q20 loss of $ 0.64 per share from revenue of $ 8.29 million.
For the full year, analysts anticipate top line of $ 61.30 million, while looking forward to loss of $ 1.9 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 80.00 million ~ $ 82.00 million
Click Here For More Historical Outlooks Of SI-BONE, Inc.
Previous Quarter Performance
SI-BONE, Inc. outlined loss for the first quarter of $ 0.47 per share, from the revenue of $ 16.82 million. The quarterly revenues boosted 12.21 percent compared with the same quarter last year. Street analysts expected SI-BONE, Inc. to report loss of $ 0.38 per share on revenue of $ 17.97 million for the first quarter. The bottom line results missed street analysts by $ 0.09 or 23.68 percent, at the same time, top line results fell short of analysts by $ 1.15 million or 6.4 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of SI-BONE, Inc.
Stock Performance
According to the previous trading day, closing price of SIBN was $ 17.10, representing a 137.50 % increase from the 52 week low of $ 7.20 and a 25.97 % decrease over the 52 week high of $ 23.10.
The company has a market capital of $ 486.10 million and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”SIBN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
SI-BONE, Inc. will be hosting a conference call at 4:30 PM eastern time on 3rd August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website si-bone.com
SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
